RENATA CASTELO: Open Payments
NPI 1831750249 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,209 in 38 payments from 23 companies in 2025. Trend: 2023 $751 · 2024 $849 · 2025 $1,209
Food & beverage: $1,123Education: $86
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. | 4 | $173 |
| AstraZeneca Pharmaceuticals LP | 2 | $146 |
| Astellas Pharma US Inc | 4 | $108 |
| E.R. Squibb & Sons, L.L.C. | 1 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $71 |
| ABBVIE INC. | 3 | $69 |
| Genmab U.S., Inc. | 2 | $56 |
| Merck Sharp & Dohme LLC | 2 | $52 |
| GENZYME CORPORATION | 2 | $43 |
| Caris MPI, Inc. | 1 | $33 |
Products named: DATROWAY, ENHERTU, REBLOZYL, Xtandi, FRUZAQLA, RUBRACA, AYVAKIT, IMBRUVICA.
Industry payments across TX — which companies pay providers there.
